Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) announced new sustainability goals aimed at enhancing its environmental commitment globally. By 2030, the company plans to source 100% of its electricity from renewable sources, and by 2040, it aims for carbon neutrality in Scope 1 and Scope 2 emissions. The initiatives also include equitable water use, zero waste to landfill, and a fully electric vehicle fleet. This follows a $300 million investment in Diversity & Inclusion and Health Equity, and aligns with the Science Based Targets Initiative for emissions reduction.
Bristol Myers Squibb (BMY) announced that the European Medicines Agency's CHMP has recommended approval of Inrebic® (fedratinib) for treating spleen enlargement in adults with specific myelofibrosis conditions. If approved by the European Commission, Inrebic will be the first once-daily oral treatment option for patients who are JAK inhibitor naïve or have failed on ruxolitinib. The CHMP opinion was based on results from pivotal studies JAKARTA and JAKARTA2. Notably, Inrebic is already approved in the U.S. for similar indications.
Bristol Myers Squibb has settled litigation with Cipla Limited regarding REVLIMID® (lenalidomide) patents. As part of the settlement, Celgene, a subsidiary of Bristol Myers, will allow Cipla to market limited amounts of generic lenalidomide in the U.S. starting after March 2022, with total sales constrained until January 31, 2026, when unlimited sales are permitted. Cipla's ability to market lenalidomide will depend on the approval of an Abbreviated New Drug Application.
Bristol Myers Squibb (NYSE:BMY) has declared a quarterly dividend of $0.49 per share, an 8.9% increase from last year's $0.45. This dividend will be payable on February 1, 2021 to stockholders of record by January 4, 2021, marking the twelfth consecutive year of increased dividend payouts. Additionally, a quarterly dividend of $0.50 on the company’s convertible preferred stock will be paid on March 1, 2021.
Bristol Myers Squibb (NYSE: BMY) has endowed a $3 million chair in chemistry at Scripps Research to boost drug discovery research. Professor Jin-Quan Yu, a prominent chemist, will be the inaugural holder. This partnership aims to facilitate the translation of academic research into biopharma, enhancing the development of new medicines. The collaboration highlights ongoing efforts to tackle global health challenges through innovative chemistry, with Yu's previous work paving the way for significant advancements in pharmaceutical chemistry.
Bristol Myers Squibb (NYSE: BMY) announced new findings from the QUAZAR® AML-001 study at the 62nd ASH Annual Meeting, highlighting the efficacy of Onureg (azacitidine tablets) for adult patients with acute myeloid leukemia (AML) in first remission. The study demonstrated that Onureg significantly improved overall survival (OS) compared to placebo, with median OS of 14.6 months for MRD+ patients vs. 10.4 months for placebo. Additionally, Onureg showed extended median relapse-free survival (RFS) and reduced hospitalization risks related to AML treatment.
Bristol Myers Squibb (NYSE: BMY) presented data on lisocabtagene maraleucel (liso-cel) at the 62nd ASH Annual Meeting, highlighting its potential in treating relapsed or refractory hematologic malignancies. In the TRANSCEND CLL 004 study, 95% of patients with CLL/SLL responded positively to liso-cel combined with ibrutinib, with high rates of complete responses. The TRANSCEND NHL 001 study indicated an 84% response rate in MCL patients. Additionally, the OUTREACH study showed promising results for liso-cel in LBCL, with 79% of outpatients achieving overall responses.
Bristol Myers Squibb (NYSE: BMY) and bluebird bio presented updated data for investigational CAR T cell therapy idecabtagene vicleucel (ide-cel) at the 62nd ASH Annual Meeting. Key findings from the Phase 1 CRB-401 study indicated an overall response rate (ORR) of 76% among 62 patients with relapsed and refractory multiple myeloma. The median progression-free survival (PFS) was 8.8 months, and median overall survival (OS) reached 34.2 months. Additionally, subgroup analyses revealed consistency in outcomes across high-risk and elderly patient populations.
Bristol Myers Squibb (NYSE: BMY) presented research from nearly 100 studies at the 62nd American Society of Hematology Annual Meeting held from December 5 to 8, 2020. The studies focus on advancements in treating blood cancers and hematologic diseases. Highlights include the latest analyses of CAR T cell therapies like liso-cel and findings on BCMA-targeted therapies for multiple myeloma. The company aims to improve patient outcomes through innovative treatments and ongoing commitment to research, emphasizing the importance of quality of life in treatment.
Bristol Myers Squibb (NYSE: BMY) announced that the European Commission has approved Opdivo (nivolumab) for adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior chemotherapy. The decision, based on the Phase 3 ATTRACTION-3 trial, highlights a 23% reduction in the risk of death with Opdivo compared to chemotherapy, improving median overall survival to 10.9 months. Opdivo's favorable safety profile showed significantly fewer treatment-related adverse events than chemotherapy. This approval allows for expanded treatment options across Europe.